market

Novo Nordisk, Lilly facing increased competition in obesity drug market


Indianapolis - April 2016: Eli Lilly and Company V

jetcityimage

While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) will likely rule the obesity drug market for the next decade, rivals such as Amgen (NASDAQ:AMGN) and Pfizer (NYSE:PFE) could soon be snacking on their

Readers Also Like:  Global stock markets head for best year since 2019
Readers Also Like:  July's CPI Report Cements US Positivity on Inflation



READ SOURCE

This website uses cookies. By continuing to use this site, you accept our use of cookies.